Risks associated with selective serotonin reuptake inhibitors in pregnancy.
about
Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysisInsomnia during pregnancy: Diagnosis and Rational InterventionsAntidepressant use in pregnancy: a critical review focused on risks and controversiesPrenatal antidepressant exposure: clinical and preclinical findings.Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.Antidepressant use in pregnancy and the risk of cardiac defectsAntidepressant use during pregnancy: comparison of data obtained from a prescription register and from antenatal care records.Links between serotonin reuptake inhibition during pregnancy and neurodevelopmental delay/spectrum disorders: A systematic review of epidemiological and physiological evidence.Paroxetine use in pregnancy and increased risk of heart defects: Evaluating the evidence.Exposed or not exposed? Exploring exposure classification in studies using administrative data to investigate outcomes following medication use during pregnancy.Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysisTreatment of nonpsychotic major depression during pregnancy: patient safety and challengesEvidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Safety of newer antidepressants in pregnancy.Serotonin reuptake inhibitors in pregnancy and the risk of major malformations: a systematic review.The safety of antidepressant drugs during pregnancy.Prevalence of antidepressant use during pregnancy in Denmark, a nation-wide cohort studyEarly-life exposure to the SSRI paroxetine exacerbates depression-like behavior in anxiety/depression-prone rats.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes.The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.Preterm birth and antidepressant medication use during pregnancy: a systematic review and meta-analysis.Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxietyAntidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction.Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomesSelective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort studyDepression and serotonin reuptake inhibitor treatment as risk factors for preterm birth.Prescribing antidepressants to pregnant women: what is a family physician to do?Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentationIncrease in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.A pilot study of heart rate variability biofeedback therapy in the treatment of perinatal depression on a specialized perinatal psychiatry inpatient unit.Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies.The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Early pharmacological treatment of autism: a rationale for developmental treatment.Perinatal depression: treatment options and dilemmas.Serotonin reuptake inhibitor-induced perinatal complications.Selective serotonin reuptake inhibitor poisoning: An evidence-based consensus guideline for out-of-hospital management.Pharmacological management of panic disorder.
P2860
Q21198704-52F5B8C6-6FF5-4F17-9CF9-547412966FA9Q28074120-662AC0C5-1F7B-43AF-976C-5E2D21929E1BQ28281407-1E52840C-9877-46BD-BA23-A58CCFE1C015Q30415540-417FF6F3-CD83-4059-AB56-60D67A183682Q31147453-B005D88A-FA87-4CB7-8D06-F7DDEE7D7E19Q33521786-FF779D09-5E50-465C-8A40-955BA434932DQ33775616-F6840551-83E0-4241-A842-B0DEDDAB178AQ33841097-5565B45E-4577-47F2-87C5-76F00CF7A247Q34047430-ADB12EAE-0484-46A6-8E02-3648715F8969Q34062619-BF3EBD23-3533-44D7-849D-714BE625956DQ34073546-6ABC4174-57D2-4071-8EA4-97242B77B404Q34144128-D45FD950-93DC-4E84-B8E2-8ECDE48BFBDFQ34237681-DC5C2F4B-7B69-4A86-A00D-1BA64CC15104Q34590507-C9C9BD3C-6353-4C29-BF73-AB1A9DD972FEQ34611697-FF80C218-A3F9-4FA5-8013-6FA4BA3F3645Q34614080-03ECB409-0355-4F0F-9CA5-0F8A699C6037Q34661348-3580E753-E850-4561-B0ED-809793F2D3D9Q34702282-8603DCC7-8288-4C80-B4D7-0E40B41F5E23Q34714284-CBF7C419-5270-4713-BD63-3299F20DD4EEQ34865036-4295C962-E665-4C9F-A0FA-3BD4BE72EF0CQ34956921-B15F025F-950B-40DE-8A11-81780B86FF62Q34981937-25DFF1E9-182B-4233-97CA-FDCC4C83B9E0Q35132422-92E27A1E-56B9-4EDF-8FD2-EDB00C1BA71AQ35252134-8C32F0AE-3633-4498-B2E3-CA235BDF80E7Q35506589-073CD18E-D39C-4B46-A5E5-49867BC0A783Q35590457-CD65915A-0895-48FB-8067-0D27AFF842AFQ35608913-51CC75E2-8ECF-4210-971C-13E341071CE0Q36045075-3C930CCE-1B42-49F3-BE06-4A1D25D3DC49Q36152982-FE7A7AB8-3CEB-4D4D-B33C-3EF97FCF36D7Q36447517-8D91FA7A-740F-45C6-9467-185E98A2DA52Q36467145-556FE544-9FB9-4CE7-BADD-2FFBE5D3630DQ36536492-70A8865A-F58A-4072-9DB2-7CF0EDA238C8Q36539778-03837CA6-AD4E-47D4-AA78-AB7DEA7456F4Q36596080-9121E93C-3791-48FE-9D94-CB92C8F43554Q36706789-89C70820-F469-4EDA-B6E5-F38F68E8EA8DQ36727667-C34F2318-C5FF-4A96-BC07-23764B90F006Q36737979-D21FB8CB-7705-4669-8FF0-6840DAB4E7BCQ36779656-8BA10EED-B54F-42F1-99CA-766AC85BC2EBQ36814510-39D5D137-1221-4A87-AF9B-B1A36A56C0E4Q36836798-78CA5D8B-EFA4-479C-AF48-001262E5557C
P2860
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@ast
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@en
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@nl
type
label
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@ast
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@en
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@nl
prefLabel
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@ast
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@en
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@nl
P2093
P1476
Risks associated with selective serotonin reuptake inhibitors in pregnancy.
@en
P2093
Pertti J Neuvonen
Timo Klaukka
P304
P356
10.1097/01.AOG.0000187302.61812.53
P407
P577
2005-12-01T00:00:00Z